Alnylam’s RNAi therapy passes second Phase 2 hypertension test, with third underway: #ACC24
Alnylam’s RNAi candidate successfully reduced 24-hour systolic blood pressure in patients with uncontrolled hypertension when added to standard of care in a mid-stage trial, reinforcing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
